Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 135-137
DOI: 10.4103/ijmpo.ijmpo_111_20
How I Treat

Breast Cancer Treatment during the COVID-19 Pandemic

Atul Batra
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Prashant Mehta
Department of Medical Oncology, Hematoncology, and Bone Marrow Transplantation, Asian Institute of Medical Sciences, Faridabad, Haryana, India
,
Amol Patel
Malignant Diseases Treatment Centre, Army Hospital Research and Referral, New Delhi, India
,
Sainath Bhethanabhotla
Department of Medical Oncology, Krishna Institute of Medical Sciences, Hyderabad, Telangana, India
,
Bivas Biswas
Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Raja Pramanik
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Chandan Krushna Das
Department of Medical Oncology, PGI, Chandigarh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

COVID-19 pandemic has challenged the prioritization of various diseases in all healthcare systems for humanity across the globe, and cancer patients are not an exception. Approximately, 160,000 new cases and 80,000 deaths are attributed to breast cancer annually and it is the most common cancer in women in India.[1] In India, most of the patients with cancer need to travel a long distance to consult an oncologist and pursue cancer treatment. Further, such patients may be predisposed to COVID-19 infection during chemotherapy sessions in day-care centers. To reduce the infections among cancer patients and also to reduce the burden on existing infrastructure of healthcare, we formulated guidance.



Publication History

Received: 28 March 2020

Accepted: 11 April 2020

Article published online:
23 May 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Globocan 2018: India Factsheet. India against Cancer. 2018 http://cancerindia.org.in/globocan-2018-india-factsheet/ October Available from: [Last accessed on 2020 Apr 07]
    PubMedGoogle Scholar
  • 2 Predict Breast. https://breast.predict.nhs.uk/tool Available from: [Last accessed on 2020 Mar 23]
    Google Scholar
  • 3 Team TNCPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. CCDCW 2020; 2: 113-22
    Google Scholar
  • 4 Liang W, Guan W, Chen R, Wang W, Li J, Xu K. et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020; 21: 335-7
    CrossrefPubMedGoogle Scholar
  • 5 Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020; 21: e181
    CrossrefPubMedGoogle Scholar
  • 6 Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L. et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet 2019; 393: 2599-612
    CrossrefPubMedGoogle Scholar
  • 7 Diaz JH. Hypothesis: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 2020; pii: taaa041
    CrossrefPubMedGoogle Scholar
  • 8 Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G. et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020; pii S0735-1097 (20) 34637-4
    Google Scholar
  • 9 http://Breast-Resource-During-COVID-19-3.30.20.pdf Available from: [Last accessed on 2020 Apr 07]
  • 10 Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP. et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: A randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2019; 20: 352-60
    CrossrefPubMedGoogle Scholar
  • 11 Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM. et al. Accelerated partial breast irradiation: Executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol 2017; 7: 73-9
    CrossrefPubMedGoogle Scholar
  • 12 http://Telemedicine.pdf Available from: [Last accessed on 2020 Apr 07]